HOME >> MEDICINE >> NEWS
Researchers identify brain pathway to explain how Fenfluramine causes weight loss

BOSTON Scientists have identified the molecular pathway in the brain that helps explain how the once-popular diet drug d-Fenfluramine (d-FEN) works to promote weight loss, a discovery reported in the July 26 issue of Science that could provide an opportunity to develop a new anti-obesity treatment without d-FEN's cardiac side effects.

The study, led by a team of researchers at Beth Israel Deaconess Medical Center (BIDMC), also suggests this same brain pathway the melanocortin system is responsible for regulation of body weight at either end of the weight spectrum from obesity at one extreme to anorexia nervosa at the other.

D-FEN, used in combination with phenteramine and known as fen-phen, was banned by the U.S. Food and Drug Administration (FDA) in 1997 after a subset of patients taking the drug developed cardiac complications.

"This study helps close the circle on the role of the melanocortin pathway and adds the serotonin system to the growing list of metabolic signals including leptin that act on the brain's melanocortin neurons, regulating food intake and body weight," explains the study's senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at BIDMC and associate professor of endocrinology and medicine at Harvard Medical School.

The diet drug d-FEN, which is the "fen" part of the fen-phen combination, first came on the market in 1992, and within five years, had been prescribed to millions of individuals who were trying to lose weight. The drug works by increasing the brain's release of serotonin, a "chemical messenger" that, among other things, helps to suppress appetite. Serotonin acts as a neurotransmitter to convey nerve impulses in the brain, and anti-obesity drugs such as fenfluramine, as well as the popular antidepressant medications fluoxetine (Prozac) and sertraline (Zoloft) work by enhancing this effect.

However, as Elmquist explains, d-FEN's popularity was relatively brief:
'"/>

Contact: Bonnie Prescott
bprescot@caregroup.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
25-Jul-2002


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... 2017 , ... Collins Concrete Coatings announced that they offer ... safety and cleanliness. This unique flooring system uses silver ion technology to resist ... for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ions attack ...
(Date:9/20/2017)... ... 20, 2017 , ... Renal Support Network’s annual essay contest ... disease. The theme “Describe a positive decision that you have made about your ... only one qualification— to have been diagnosed with chronic kidney disease. This year ...
(Date:9/20/2017)... Lexington, Massachusetts (PRWEB) , ... ... ... Corporation , a software company specializing in medical device compliance and commercialization, ... engineering in risk management activities. , FDA is more adamant than ever ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation ... the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the ... than 40 speakers — representing such thought-leading companies as JP Morgan Chase, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and innovation, the company recently unveiled a redesigned website. The new site – ... work of building owners, architects, contractors and other industry users that Garland serves. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... -- Eli Lilly and Company (NYSE: LLY ... more efficiently focus resources on developing new medicines ... reductions, including those from a U.S. voluntary early ... positions. With the streamlining efforts ... $500 million that will begin to be realized ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology:
Cached News: